Add like
Add dislike
Add to saved papers

Long-term followup of 1121 cases of carcinoma in situ.

A series of 1121 patients with carcinoma in situ have been followed for 5 to 25 years. Recurrences of in situ lesions and development of invasive cancer wwere found, often many years after treatment. Thereapeutic conization was performed in 795 patients, of which 19 (2.3%) had recurrent carcinoma in situ and 7 patients (0.9%) developed invasive cancer. The corresponding figures for 238 patients treated with hysterectomy were, respectively, 3 (1.2%) and 5 (2.1%). The invasive lesions appeared after treatment several years later than the in situ lesions. It is stressed that women having once had in situ carcinoma of the cervix will always be at some risk, and therefore should be carefully followed for a much longer time than the conventional 5 years. Of 42 cases of preinvasive carcinoma extending to the border of the surgical specimen in which conization was performed, 25 were not immediately treated but only observed. Four of these patients developed recurrence from 2 to 6 years after treatment, while 21 are well after a followup period of between 5 and 15 years.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app